Followers | 37 |
Posts | 4190 |
Boards Moderated | 0 |
Alias Born | 10/18/2016 |
Wednesday, November 29, 2017 9:42:41 AM
- IGC is scheduled to market a liquid formulation of its drug, IGC-AD1 (Hyalolex), in 2018; company is eyeing markets in Germany, Canada and U.S. states where licensed medical cannabis has been legalized
- IGC is exclusive licensee of a U.S. patent filing for possible THC-based Alzheimer’s disease (AD) therapy, which, if approved, could give it a huge advantage in competition for share of global drug market for AD
- Alzheimer’s Association: Some five million Americans have AD or some form of dementia, and $259 billion is being spent on treatments in 2017 — a number that could skyrocket to $1.1 trillion by 2050
India Globalization Capital, Inc. (NYSE American: IGC) sees opportunities in 2018, primarily from the distribution, in Germany, of its cannabinoid-based therapies, including IGC-AD1 (Hyalolex). It also sees the commercialization in 2018 of Hyalolex in a non-inebriating liquid supplement version. IGC has identified a number of U.S. states, as well as Canada and Germany, as target markets in the future.
The Maryland-based company is focused on the development of cannabis-based combination therapies to treat eating disorders, nausea, Alzheimer’s disease (AD), pain, and possibly Parkinson’s. It is also researching drugs that treat epilepsy in dogs and cats. The firm already has a portfolio of patent filings and four lead products that address these conditions.
IGC is the exclusive licensee of the U.S patent filing, “THC As A Potential Therapeutic Agent For Alzheimer’s Disease.” This gives IGC an advantage in the global market of AD drugs.
The global potential of AD treatment in massive. IGC sees worldwide application of its cannabinoid-based therapies (http://nnw.fm/JK2Bn). In the U.S. alone, the Alzheimer’s Association estimates that treatment of AD and other forms of dementia will cost about $259 billion in 2017 — and that number could rise to $1.1 trillion by 2050 (http://nnw.fm/tAfs5). The Association said some five million Americans have AD today, and that number could rise to 16 million by 2050.
Because AD begins well prior to the appearance of symptoms, a drug such as IGC-AD1, which has shown an ability to lower production/aggregation of Aß plaque without neurotoxic effects or inebriation, could be taken as a prophylactic treatment to prevent AD.
IGC has entered into a Memorandum of Understanding (MOU) with Hamburg, Germany-based MediCann Handels GMBH for the distribution of IGC’s cannabinoid-based therapies, including IGC-AD1, to pharmacies, apothecaries and other licensed outlets that can legally sell cannabinoid-based products (http://nnw.fm/52Jyc). The MOU calls for MediCann to provide the capital required for the import, storage, transportation, sales and marketing of the products. In Germany, the number of dementia cases is 1.6 million-plus, most commonly caused by AD, per company data.
In a news release, Ram Mukunda, CEO of IGC, said the company would market, through medical dispensaries, a non-inebriating liquid supplement version of IGC-AD1 in 2018, with target markets spanning Germany, Canada and certain states within the U.S. Cumulatively, these markets have some 7.8 million patients with AD, the company said (http://nnw.fm/0UZzB).
For more information, visit the company’s website at www.IGCinc.us
Recent IGC News
- IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two • Business Wire • 04/16/2024 11:00:00 AM
- IGC Pharma Adds Advisor in Artificial Intelligence • Business Wire • 04/09/2024 01:00:00 PM
- IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock • Business Wire • 03/26/2024 07:00:00 PM
- IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation • Business Wire • 03/20/2024 03:00:00 PM
- IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024 • Business Wire • 03/20/2024 11:00:00 AM
- IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline • Business Wire • 03/12/2024 07:00:00 PM
- Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model • Business Wire • 02/28/2024 06:00:00 PM
- IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target • Business Wire • 02/23/2024 05:01:00 PM
- IGC Pharma Reports Third Quarter Fiscal 2024 Results • Business Wire • 02/17/2024 12:05:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:03:00 PM
- IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model • Business Wire • 02/01/2024 02:20:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/31/2024 09:04:23 PM
- IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s • Business Wire • 01/23/2024 02:20:00 PM
- IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial • Business Wire • 01/17/2024 02:20:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/09/2024 05:15:07 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/29/2023 09:54:29 PM
- Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s • Business Wire • 12/19/2023 02:20:00 PM
- IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024 • Business Wire • 12/13/2023 02:30:00 PM
- IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials • Business Wire • 12/06/2023 01:30:00 PM
- IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives • Business Wire • 11/21/2023 01:30:00 PM
- IGC Pharma Reports Second Quarter Fiscal 2024 Results • Business Wire • 11/13/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:15:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 09:21:48 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/27/2023 08:38:17 PM
- IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy • Business Wire • 10/19/2023 07:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM